Related references
Note: Only part of the references are listed.Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations
E. David Crawford et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2019)
Population pharmacokinetic-pharmacodynamic modelling of the relationship between testosterone and prostate specific antigen in patients with prostate cancer during treatment with leuprorelin
Nelleke Snelder et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Discordance between testosterone measurement methods in castrated prostate cancer patients
Melanie Rouleau et al.
ENDOCRINE CONNECTIONS (2019)
Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer-time for a rethink?
Sonja Cabarkapa et al.
PROSTATE INTERNATIONAL (2018)
Testosterone suppression in the treatment of recurrent or metastatic prostate cancer - A Canadian consensus statement
Laurence Klotz et al.
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL (2018)
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
Philip Cornford et al.
EUROPEAN UROLOGY (2017)
Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer
Laurence Klotz et al.
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL (2017)
Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics
T. H. T. Nguyen et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Modeling Testosterone Circadian Rhythm in Hypogonadal Males: Effect of Age and Circannual Variations
Mario Gonzalez-Sales et al.
AAPS JOURNAL (2016)
Contemporary agents in the management of metastatic castration-resistant prostate cancer
Anil Kapoor et al.
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL (2016)
Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details
Maha Hussain et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Current opinion on the role of testosterone in the development of prostate cancer: a dynamic model
Xiaohui Xu et al.
BMC CANCER (2015)
Relationships Between Times to Testosterone and Prostate-Specific Antigen Rises During the First Off-Treatment Interval of Intermittent Androgen Deprivation are Prognostic for Castration Resistance in Men With Nonmetastatic Prostate Cancer
Kevin F. Kuo et al.
CLINICAL GENITOURINARY CANCER (2015)
Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT
Laurence Klotz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Changes in levels of prostate-specific antigen and testosterone following discontinuation of long-term hormone therapy for non-metastatic prostate cancer
Kunihisa Yamaguchi et al.
JOURNAL OF MEDICAL INVESTIGATION (2014)
Molecular Pathways: Inhibiting Steroid Biosynthesis in Prostate Cancer
Roberta Ferraldeschi et al.
CLINICAL CANCER RESEARCH (2013)
Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?
Tom Pickles et al.
BJU INTERNATIONAL (2012)
Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?
L. Klotz et al.
CURRENT ONCOLOGY (2012)
Comparison of Nonmem 7.2 estimation methods and parallel processing efficiency on a target-mediated drug disposition model
Leonid Gibiansky et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2012)
Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer
A. Spitz et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2012)
Pharmacokinetic/Pharmacodynamic Model of the Testosterone Effects of Triptorelin Administered in Sustained Release Formulations in Patients with Prostate Cancer
Elba Romero et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy
Juan Morote et al.
BJU INTERNATIONAL (2009)
Semiparametric Distributions With Estimated Shape Parameters
Klas J. F. Petersson et al.
PHARMACEUTICAL RESEARCH (2009)
Evaluation of drugs in pediatrics using K-PD models: perspectives
M. Tod
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2008)
International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients
Greg L. Shaw et al.
BJU INTERNATIONAL (2007)
Locally advanced prostate cancer - Biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy
Nicholas Bruchovsky et al.
CANCER (2007)
Modelling response time profiles in the absence of drug concentrations: Definition and performance evaluation of the K-PD model
P. Jacqmin et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2007)
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Nancy L. Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer - Clinical parameters
Nicholas Bruchovsky et al.
CANCER (2006)
PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM
L Lindbom et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2005)
Effective testosterone suppression for patients with prostate cancer: Is there a best castration?
MG Oefelein et al.
UROLOGY (2003)
The development of androgen-independent prostate cancer
BJ Feldman et al.
NATURE REVIEWS CANCER (2001)
Share Paper
